From July 1, 2023 to September 30, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 2,000,000 shares, representing 0.12% for CNY 72.2 million under the buyback announced on April 5, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.38 CNY | -.--% | -0.87% | -51.60% |
26/06 | Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology | MT |
18/06 | Walvax Terminates Coronavirus Vaccine Trials Due to Mutations | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.60% | 2.5B | |
+2.08% | 95.18B | |
-4.34% | 37.55B | |
+75.60% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B | |
+6.22% | 9.09B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.